Impact of tumor, patient and immune characteristics on talquetamab-mediated lysis, T-cell activation, and degranulation. The impact of tumor and patient characteristics (A) and immune characteristics (B) on talquetamab-mediated activity was assessed by constructing dose-response curves for talquetamab-mediated MM cell lysis (panels I), talquetamab-mediated T-cell activation based on frequency of CD25⁺ T cells (panels II), and talquetamab-mediated T-cell degranulation based on frequency of CD107a⁺ T cells (panels III), according to median expression levels (GPRC5D, BCMA), median percentage of immune cell subsets (T cells, Tregs, PD-1⁺ T cells, HLA-DR⁺ T cells, naïve T cells), median E:T ratio, median age, as well as presence of high-risk cytogenetic aberrations. Patient samples were obtained from 13 NDMM, 17 daratumumab-naïve RRMM, and 15 daratumumab-refractory RRMM patients. Data represent mean ± SEM, samples with a value ≤ median value of all tested samples are depicted in blue and > median value in red. Groups were compared by nonlinear regression analysis. P values are provided.